2026-07-24T11:32:28Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119252026-07-20T07:58:10Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

García-Alfonso, P. c1ab80eb-103e-45d0-a81e-94907d63acde 500 Saiz Rodríguez, Miriam 826 600 0000-0002-1660-3135 Mondéjar, R. 15df83dd-7555-4407-a67a-e5204a115832 500 Salazar, J. b3e199e9-2fa3-43f2-bd57-ab8f31948266 500 Páez, D. 4e42a042-e3d2-4389-85eb-5eb87fb0568b 500 Borobia, A. M. 2d77bb38-c63f-4ada-847f-33e0458d201b 500 Safont, M. J. d44f9875-9aa1-469c-8289-22123650a0a7 500 García-García, I. 75062afc-f868-4b1f-82a4-a80de284ba13 500 Colomer, R. 2c134180-2dfc-43c2-a007-0dcc76a00abe 500 García-González, X. 29e20fd8-6c51-477e-b6d7-53c938c447d0 500 Herrero, M. J. 4c6be4b7-73a0-4863-8b02-e07c75acc030 500 López-Fernández, L. A. 78d7192c-13df-4752-bdcb-fe056464bf31 500 Abad-Santos, F. b7ed6eb7-ce2b-4864-9094-d336f739b8e8 500 2026-07-17T11:43:27Z 2026-07-17T11:43:27Z 2022-03 1699-048X https://hdl.handle.net/10259/11925 10.1007/s12094-021-02708-4 1699-3055 5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction in clearance and a longer half-life of 5-FU. It is advisable to determine if a DPD deficiency exists before administering these drugs by genotyping DPYD gene polymorphisms. The objective of this consensus of experts, in which representatives from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology participated, is to establish clear recommendations for the implementation of genotype and/or phenotype testing for DPD deficiency in patients who are candidates to receive fluoropyrimidines. The genotyping of DPYD previous to treatment classifies individuals as normal, intermediate, or poor metabolizers. Normal metabolizers do not require changes in the initial dose, intermediate metabolizers should start treatment with fluoropyrimidines at doses reduced to 50%, and poor metabolizers are contraindicated for fluoropyrimidines. This project has been financed with SEOM and SEFF resources. eng Springer Nature Clinical and Translational Oncology. 2022, V. 24, n. 3, p. 483-494 https://doi.org/10.1007/s12094-021-02708-4 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess 5-fluorouracil Capecitabine Dihydropyrimidine dehydrogenase Genotypes Pharmacogenetics Toxicity Farmacogenómica Pharmacogenomics Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Clinical and Translational Oncology 24 3 483 494 THUMBNAIL García-CTO_2022.pdf.jpg García-CTO_2022.pdf.jpg IM Thumbnail image/jpeg 4732 https://riubu.ubu.es/bitstream/10259/11925/4/Garc%c3%ada-CTO_2022.pdf.jpg 70e049ba3c56c9cbf393a59da21a0c8f MD5 4 LICENSE license.txt license.txt text/plain; charset=utf-8 1362 https://riubu.ubu.es/bitstream/10259/11925/3/license.txt 5d013bfa6e473ff0db22cd82a4d71a70 MD5 3 CC-LICENSE license_rdf license_rdf application/rdf+xml; charset=utf-8 908 https://riubu.ubu.es/bitstream/10259/11925/2/license_rdf 0175ea4a2d4caec4bbcc37e300941108 MD5 2 ORIGINAL García-CTO_2022.pdf García-CTO_2022.pdf application/pdf 948631 https://riubu.ubu.es/bitstream/10259/11925/1/Garc%c3%ada-CTO_2022.pdf 79617dddd9a946af618cbf2681e720a0 MD5 1 10259/11925 oai:riubu.ubu.es:10259/11925 2026-07-20 09:58:10.708 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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